Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(33.3%)

Phase 3

2(33.3%)

Phase 2

2(33.3%)

6Total

Phase 1(2)

Phase 3(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07298434Phase 3Active Not Recruiting

Study of VYD2311 for the Prevention of COVID-19

Role: lead

NCT06039449Phase 3Completed

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

Role: lead

NCT06523153Phase 1Active Not Recruiting

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

Role: lead

NCT04859517Phase 2Terminated

Evaluation of ADG20 for the Prevention of COVID-19

Role: lead

NCT06004128Unknown

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

Role: lead

NCT05791318Phase 1Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants

Role: lead

NCT04805671Phase 2Terminated

Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

Role: lead

All 7 trials loaded